Since the concept of ADC was proposed in 1900, it has existed as a new type of cancer treatment method. Although its development has faced many challenges over the past century, top scientists in the relevant fields around the world have been conducting years of experiments and iterations to improve safety, reduce off-target effects, and … Read more
△ A grand contribution, 1 main forum, 5 sub-forums, 9 thematic forums, hundreds of industry leaders, many renowned clinical PIs and dozens of CMOs gathered, a thousand-person conference awaits you! ▼ Antibody-drug conjugates (ADCs) are currently developing rapidly, utilizing antibodies to selectively deliver cytotoxic drugs to tumor sites. As of May 2021, the U.S. Food … Read more
Antibody-drug conjugates (ADCs) consist of linker, payload, and monoclonal antibodies (mAb). They combine the advantages of high specificity targeting ability and potent cytotoxic effects, achieving precise and efficient destruction of cancer cells, making them one of the hot topics in anticancer drug development.Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA … Read more
To build a global highland for the future ADC/RDC industry, Chengdu Medical City plans to hold the first Future XDC New Drug Conference from April 18 to 19, 2024! The conference, themed “Co-creating the Future of the Conjugated Drug Industry,” is organized by Tongxi Yi Planning, featuring a main forum and nine thematic forums. Experts … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more
Antibody-drug conjugates (ADCs) have become a popular avenue in tumor treatment in recent years, typically covalently linking monoclonal antibodies (mAbs) with cytotoxic drugs (payloads) via chemically synthesized linkers. ADCs combine the advantages of highly specific targeting capabilities and effective killing actions, achieving precise and efficient clearance of cancer cells.Figure 1. Structure and characteristics of ADC … Read more
Antibody-drug conjugates (ADC) are a new class of targeted drugs composed of monoclonal antibodies (mAbs), cytotoxic drugs, and linkers that connect the two. They utilize the targeting capability of antibodies to selectively deliver cytotoxic molecules to tumor cells, exerting anti-cancer effects while avoiding impacts on healthy cells. ADC drugs have rapidly developed in the field … Read more
* For reference by medical professionals only What Issues Should Be Addressed During the Infusion of ADC Drugs for Breast Cancer? ADC drugs combine the precise targeting of antibody drugs with the efficient killing advantage of cytotoxic drugs, gradually changing the treatment landscape for breast cancer. Currently, ADC drugs that have entered clinical practice in … Read more
LC-MS/MS ADC Drug Biological Analysis A Dual Advantage in Speed and Cost 0 1 Definition of Antibody-Drug Conjugates (ADC) Antibody-drug conjugates (ADC) consist of an antibody, a cytotoxic drug, and a linker (as shown in Figure 1[1]), and are considered an innovative therapeutic approach targeting various types of tumors and cancers. They can enhance the … Read more
Click below to follow and never miss cancer knowledge~ Author: Guo Lin When it comes to cancer treatment, chemotherapy, surgery, and radiotherapy are the most familiar traditional methods. However, with the advancement of anti-cancer technology, a new type of “smart” anti-cancer drug that combines the advantages of chemotherapy and targeted drugs—Antibody Drug Conjugates (ADC)—has gradually … Read more